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PRODUCTION OF  TRANSFORMING GROWTH FACTOR /3 
BY HUMAN T LYMPHOCYTES AND ITS POTENTIAL  ROLE 
IN THE REGULAT ION OF T CELL  GROWTH 
BY JOHN H. KEHRL,* LALAGE M. WAKEFIELD,* ANITA B. ROBERTS,* 
SONIA JAKOWLEW,* MELCHOR ALVAREZ-MON, ~ RIK DERYNCK, I 
MICHAEL B. SPORN,* AND ANTHONY S. FAUCI* 
From the *Laboratory of lmmunoregulation, National Institute of Allergy and Infectious 
Diseases, the *Laboratory of Chemoprevention, National Cancer Institute, National Institutes of 
Health, Bethesda, Maryland 20892; the ~Servei of Internal Medicine 1, Clinica Puerta de 
Hierro, Madrid, Spain; and the RDepartment of Molecular Biology, Genentech, Incorporated, 
South San Francisco, California 94080 
Transforming rowth factors (TGFs) 1 are polypeptides that reversibly induce 
certain nonneoplastic cells to express a transformed phenotype and to undergo 
anchorage-independent growth (1, 2). One of these,TGF-/3, is a 25 kD homodi- 
meric protein held together by disulfide bonds. TGF-/3 has been purified and 
partially sequenced, and its gene has been cloned (3-7). Using Northern blots, 
human TGF-/3 mRNA has been identified in a variety of cell types including 
mitogen-activated nonadherent PBMC (7). TGF-/3 binds to a unique receptor 
and has no known homology to other growth factors (8, 9). It was originally 
characterized by its ability to enhance the growth of normal rat kidney cells in 
soft agar when present with epidermal growth factor (EGF) (10). The precise 
mechanism of this effect is unknown, although TGF-/3 has been shown to 
upregulate EGF receptors in NRK cells (11). Subsequently, TGF-/3 has been 
shown to have both growth-enhancing and growth-inhibitory properties, and the 
effect hat predominates is dependent upon the particular cell type and the other 
growth factors present (12, 13). For example, TGF-/3 synergized with platelet- 
derived growth factor to stimulate colony formation by a 3T3 cell line that had 
been transfected with c-myc, but inhibited colony formation by the same cell 
stimulated with EGF (12). 
It has been clearly shown that a variety of soluble factors can influence the 
growth and effector function of murine and human lymphocytes (14). The 
present study examines the potential role of TGF-/3 in modulating human T 
lymphocyte function. We show that the addition of exogenous TGF-/3 to cultures 
of T lymphocytes inhibits IL-2-dependent T cell proliferation, and that activated 
T cells themselves synthesize and secrete TGF-/3. 
This work was partially supported by a grant from the Fondo de Investigaciones de la Seguridad 
Social. Address correspondence to J. Kehrl, National Institutes ofHealth, Building 10, Room 11B- 
13, Bethesda, MD 20892. 
l Abbreviations u ed in this paper: EGF, epidermal growth factor; NRK, normal rat kidney; TCE, 
T cell enriched; TGF, transforming growth factor. 
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Materials and Methods 
Cell Preparation. Human tonsils were obtained at tonsillectomy from 7-20-yr-old 
patients with chronic tonsillitis, and were dispersed into single-cell suspensions. T cell- 
enriched (TCE) populations were obtained from tonsillar mononuclear cells by rosetting 
with 2-aminoethylisothiouronium bromide-treated sheep erythrocytes (15). The TCE 
fractions were further purified by passage over nylon wool columns. The Jurkat cell line, 
a human T cell leukemia, was kindly donated by Dr. Warner Greene. 
Factors. TGF-/3 was purified from human platelets as previously described (3). The 
TGF-13 was homogenous by analysis on SDS-polyacrylamide g ls. rIL-2 (lot LP210) was 
kindly provided by Cetus Corp. (Emeryville, CA); it was 96% pure by SDS gel analysis 
and contained <0.04 ng endotoxin per 106 U (16). 1U IL-2 was defined as the amount 
of IL-2 required to induce half-maximal stimulation of an IL-2-dependent T cell line, 
HT2. 
Culture Conditions. The TCE fractions were cultured with Con A (10 #g/ml; Sigma 
Chemical Co., St. Louis, MO) for 12 h in RPMI 1640 plus 10% FCS (Dutchland 
Laboratories, Inc., Denver, PA), washed with RPMI containing 0.3 M methyl-a-D- 
mannopyranoside (Calbiochem-Behring Corp., La Jolla, CA), and recultured with various 
concentrations of TGF-/3 in the serum-free medium HB 102 (Hana Media, Berkeley, CA), 
with 25-50 U/ml IL-2. Cells were cultured as 5 x 104 cells/well in 96-well plates (Costar, 
Cambridge, MA) for time periods as indicated. DNA synthesis was measured uring the 
last 16 h of culture. Cells were pulsed with 1 #Ci of [3H]thymidine (6.7 Ci/mM; New 
England Nuclear, Boston, MA). Incorporation of [3H]thymidine was measured by standard 
liquid scintillation counting techniques after harvesting by a Skatron harvester (Skatron, 
Inc., Sterling, VA). In other experiments, the TCE fractions were cultured with PHA (2 
#g/ml) in serum-containing media, and transferred to serum-free media at the indicated 
times. 
Immunofluorescence. Cells (106 per 0.1 ml) to be analyzed for surface immunofluores- 
cence were incubated for 30 min on ice with 5 #l of either OKT3-FITC (Ortho Diagnostics, 
Inc., Raritan, N J), anti-IL-2-R (Becton Dickinson Monoclonal Center, Mountain View, 
CA), or anti-transferrin receptor-phycoerythrin (Becton Dickinson Monoclonal Center). 
The cells were then washed twice with HBSS containing 0.1% human serum albumin and 
0.02% azide, and analyzed on a FACS (FACS II.II; Becton Dickinson Immunocytometry 
Systems, Mountain View, CA). Control cells were unstained. For each sample, 20,000 or 
30,000 light-scatter-gated viable cells were collected. Fluorescence data were collected 
with logarithmic ampification, and the specific ell immunofluorescence was expressed as 
channel numbers on a log scale. The mean fluorescence intensity was calculated by 
integrating the fluorescent histograms for the positive cells (compared to control cells). 
Binding Assay. TGF-B was iodinated to a specific activity of 2-4 mCi/nmol using a 
modified chloramine T method (8). T cells were incubated for 2 h at 37°C in serum-free 
media to remove bound endogenous TGF-13. After washing, cells were resuspended in
binding buffer (DMEM with 0.1% BSA, 25 mM Hepes, pH 7.4) containing 1-500 pM 
J25I-TGF-/3 at 10 6 cells per 0.2 ml. Nonspecific binding was determined in the presence 
of 10 nM cold TGF-13. Samples were incubated for 2 h at 25°C in a CO2 atmosphere with 
constant agitation. The cells were then spun down and the supernatants were counted in 
a gamma counter to determine the free ligand concentration. The cell pellet was resus- 
pended in binding buffer and spun through a silicone oil/paraffin oil layer, and the 
resulting pellet was counted to determine bound ligand. 
TGF-13 Assays. Supernatants o be assayed for TGF-13 were obtained from T cells 
cultured from serum-free media in the presence or absence of PHA. After harvesting, 1
mM PMSF (Pierce Chemical Co., Rockford, IL) was added to each supernatant. Subse- 
quently, the supernatants were dialyzed against 1 M acetic acid, lyophilized to dryness, 
and reconstituted in a solution of one part 4 mM HCI plus three parts DMEM. The 
bioassay for TGF-/3 depends upon the ability of TGF-t3 to induce anchorage-independent 
growth of normal rat kidney (NRK) fibroblasts grown in the presence of 5 ng/ml EGF in 
soft agar. The soft agar assay was performed as previously described by measuring colony 
formation in 0.3 % agar (10). Colonies were stained after 7 d of incubation, and those >62 
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#M in diameter were counted using an Omnicon image analysis ystem programmed to
count a 5-cm 2 area ofa 35-mm-diam plate. 
The radioreceptor assay for TGF-13, a competitive binding assay that uses A549 cells, 
was performed as previously described (8). A549 cells were incubated with I~SI-TGF-/3 
for 2 h at 25°C in 5% CO2 in the presence of various dilutions of the test supernatant. 
After incubation, the cells were washed four times with cold HBSS (Gibco Laboratories, 
Grand Island, NY) containing 0.1% BSA. The cells were solubilized with 0.6 ml Triton 
solution (20 mM Hepes, 2% Triton X-100, 10% glycerol, 0.01% BSA, pH 7.4) by a 20- 
min incubation at room temperature, and counted on a gamma counter. A TGF-13 standard 
curve was constructed using serial dilutions of a known amount of TGF-13. 
Northern Blots. Total RNA was isolated from T cells using a guanidine thiocynanate 
method. The purified total RNA was electrophoresed in agarose-formaldehyde gels and 
transferred to either nitrocellulose (Schliecher and Schuell, Keene, NH) or Gene Screen 
II (New England Nuclear). The size-fractionated RNA was probed using a 3~P-labelled 
Eco R1 insert from ~,/3C1 under high stringency conditions (7). As previously reported 
(7), the TGF-13 probe recognized an mRNA of ~2.5 kb. 
Results 
TGF-t3 Suppresses IL-2-dependent T Cell Proliferation and Partially Inhibits IL-2- 
R and Transferrin Receptor Expression. Since serum is a source of TGF-/3 and a 
variety of binding proteins for TGF-/3 could be present in serum, all of the 
experiments examining the effects of TGF-13 were performed in serum-free 
media. T cells were stimulated with Con A for 8-12 h in serum-containing 
media, washed, and recultured in serum-free media. This duration of stimulation 
is sufficient for cellular activation and IL-2-R expression, but not for subsequent 
progression into S phase unless exogenous IL-2 is present (17, 18). Fig. 1 (top) 
shows the effect of TGF-13 on DNA synthesis by Con A-activated tonsillar T 
lymphocytes that were cultured in the presence of IL-2. Optimal concentrations 
of TGF-/3 suppressed DNA synthesis by 60-80%. This degree of suppression was 
present 3, 4, and 5 d after the addition of IL-2 and TGF-/3 (Fig. 1, bottom). TGF- 
/3 was not toxic to the T cells, as judged by trypan blue dye exclusion. 
Additionally, the effects of 2 ng/ml of TGF-/3 on IL-2-dependent T cell 
proliferation were examined as a function of IL-2 concentrations (Table I). TGF- 
13 was most suppressive at the lower IL-2 concentrations. At higher IL-2 concen- 
trations (100 and 300 U/ml), the degree of suppression decreased, although 
some suppression was present even at 300 U/ml. The degree of suppression was 
greater at day 5 than at day 3. Thus, by regulating the amount of IL-2 and TGF- 
/3 present, the amount of T cell proliferation can be regulated. 
The interaction of IL-2 with its receptor on T cells has been shown (19) to be 
of primary importance in T cell growth, and satisfies the criteria for an autocrine 
system. One of the consequences of this interaction is an upregulation in cell- 
surface membrane IL-2-R (20, 21). IL-2 has also been shown (22-24) to be an 
important signal in the upregulation of another eceptor, the transferrin recep- 
tor, which is thought o be important in cellular growth and is found on rapidly 
dividing cells. A potential mechanism whereby TGF-/3 might inhibit the growth 
of T cells is by interfering with the normal expression of either of these receptors. 
In Fig. 2, the effects of TGF-/3 on IL-2 and transferrin receptor levels are 
examined using immunofluorescence with a mAb against he transferrin receptor 
and an anti-IL-2-R mAb. Exposure of previously activated T cells to IL-2 for 
16 h was sufficient o result in enhanced expression of both the IL-2-R and the 
1040 TRANSFORMING GROWTH FACTOR /3 FROM T CELLS 
80 
60 
Z 
=m 
@ 
20 
24 
1 l I I I 
12 
6 D3 
0.06 0.2 0.6 2 6 
TGF,~ (ng/ml) 
FIC, URE 1. Suppression of T cell DNA synthesis by TGF-/3. The TCE fractions were cultured 
with Con A, 10 I~g/ml, for 12 h in RPMI 1640 plus 10% FCS; washed with RPMI containing 
0.3 M methyl-a-D-mannopyranoside; and recultured with IL-2 and various concentrations of
TGF-/3 in HB102 media. Data in the upper panel are the mean _SEM for four experiments 
that were harvested on day 3 after a 16-h pulse with [SH]thymidine. Percent suppression is
calculated as (1 - [cpm in presence of TGF-/3] - [background])/([cpm in absence of TGF-13] -
[background]). Data in the lower panel are [SH]thymidine incorporation from one experiment 
harvested on different days (days 3, 4, and 5). 
TABLE I 
Effect of TGF-[3 on IL-2-dependent T Cell Proliferation as a 
Function of lL-2 Concentration 
IL-2 
(U/ml) 
[nH]Thymidine incorpora- 
tion day 3 (cpm/105 cells) 
[SH]Thymidine incorpora- 
tion day 5 (cpm/10 ~cells) 
No TGF-/3 TGF-/3* No TGF-/3 TGF-/3* 
0 7,302 3,721 9,175 1,523 
3 10,531 3,954 9,581 1,464 
10 34,241 11,474 22,440 3,942 
30 82,930 45,411 79,251 9,620 
100 92,766 79,442 170,323 96,688 
300 102,645 88,109 189,512 161,306 
T cells were activated with Con A and cultured in the presence or 
absence of IL-2. [SHlThymidine incorporation was measured as de- 
scribed in the Materials and Methods, 
* TGF-/3 present at 2 ng/ml. 
t rans fer r in  receptor .  I f  TGF-~ was present  in the  cu l tu re  together  wi th the  IL -  
2, the  increase  in dens i ty  o f  both  receptors  was ab lated.  Add i t iona l ly ,  the  presence  
o f  TGF- /3  in cu l tu re  reduced  the  number  o f  I L -2R  ÷ cells f rom 99 to 76%.  TGF-  
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FIGURE 2. Regulation of the IL-2-R and transferrin receptors on human T cells by IL-2 and 
TGF-fl. T cells were purified from tonsillar mononuclear cells and activated with 2 pg/ml of 
PHA for 4 d in RPMI with 10% FCS. The cells were harvested and replated in 24-well Costar 
plates at 106 cells/well in HB102 media in the presence of media lone, 25 p/ml of IL-2, or 2 
ng/ml TGF-fl plus IL-2. 16 h later, the cells were harvested and immunofluorescently s ained 
with an anti-lL-2-R mAb, and an anti-transferrin receptor mAb. The cells were analyzed 
with a FACS. The mean fluorescent intensity (MFI) of the positive cells is indicated in the 
upper ight portion of each FACS pattern. The IL-2-R is referred to as Tac. 
/3 did not modulate T3-R expression (data not shown). Thus, a possible mecha- 
nism whereby TGF-/3 suppresses T cell proliferation is by interfering with the 
normal regulation of  IL-2-R. The  diminished expression of  the transferrin 
receptor may be a secondary effect related to the effects of TGF-f l  on the IL-2- 
R. 
T Cell Activation Results in Upregulation of TGF-fl-R. A binding assay using 
]25I-iabeled TGF-fl  has been previously developed and used to demonstrate the 
presence of  TGF-/3 receptors on a variety of  cell lines (8, 9). We examined the 
expression of  TGF-f l  receptors on unstimulated and activated T cells. The  
unstimulated T cells had low numbers of  high-affinity TGF-fl-R. When the T 
cells were cultured in the presence of  PHA for 36 h, the number  of TGF-fl-R 
per cell increased approximately sixfold compared to cells cultured in the absence 
of  PHA (Fig. 3). The  affinity of  the TGF-fl-R for its ligand was not significantly 
changed when the T lymphocytes were stimulated. Although the number  of 
TGF-fl-R present on activated T cells is less than almost all the cell lines previously 
tested, the affinity of the receptor on T cells is higher by 5-10-fold (8, 9). The 
effect of IL-2 on TGF-fl  binding was also examined. T cells were activated for 
12 h with Con A, washed with a-methyl mannoside, and recultured for 24 h in 
the presence or absence of  IL-2. The  presence of IL-2 did not alter the number  
or the affinity of  the TGF-fl-R present (data not shown). Thus, resting T cells 
express low numbers of  TGF-fl-R, and cellular activation results in a substantial 
increase in their number.  
T Cell Activation Results in Appearance of TGF-fl mRNA in T Cells and Increased 
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FIGtJRE 3. T cell activation results in an increase inthe number of TGF-/3 binding sites per 
cell. Typical curves for the specific binding of ~SI-TGF-/3 to activated and unactivated tonsillar 
T lymphocytes. Scatchard analysis of the binding curves revealed the indicated affinity and 
number of binding sites. Unstimulated (O), Kd = 2 pM; sites/cell, 58. PHA-stimulated (O), Kd 
= 5.1; sites/cell, 380. 1 pM of TGF-/3 corresponds to 25 pg/ml. 
Production of TGF-13 in Culture Supernatants. The previous data showed that T 
cells have receptors for TGF-/3, that exogenous TGF-/3 can modulate T cell DNA 
synthesis, and that exogenous TGF-/3 interferes with the normal regulation of 
IL-2 and transferrin receptors. The likelihood that TGF-/3 is an important 
regulator of T cell function would be considerably enhanced if T cells themselves 
made TGF-J3. Previous experiments (7) showed the induction of TGF-/3 mRNA 
in mitogen-stimulated PBMC. To ascertain whether stimulated T cells actively 
secreted TGF-/3, we determined whether supernatants conditioned by either 
unstimulated or stimulated T cells contained TGF-/3 biologic activity. We also 
examined purified T cells for the presence of TGF-~ mRNA and examined the 
temporal relationship between induction of TGF-/3 mRNA and the secretion of 
TGF-/3 by activated T cells. 
To show TGF-/3 biologic activity in conditioned media, T cells were either 
cultured in serum-free media in the presence or absence of PHA, or initially 
cultured in serum-containing media in the presence or absence of PHA, and 
after extensive washing, transferred to serum-free conditions. The collected 
supernatants were assayed for TGF-/3 biologic activity using a soft agar assay. 
This assay relies upon the ability of TGF-/3 to enhance the growth of NRK cells 
in agar in the presence of EGF (10). Supernatants conditioned by unactivated T 
cells had low levels of TGF-/3-1ike biologic activity (0.6-1.6 pM), while superna- 
rants from PHA-activated T cells had levels 10-50-fold higher (20-74 pM, Table 
lI). To confirm that the TGF-/3 like biologic activity was indeed due to TGF-/3, 
the superantants were also assayed in a competitive radioreceptor assay (8). This 
assay detects TGF-/3 in an unknown sample by its ability to inhibit the binding of 
radiolabeled TGF-/3 to a cell line that expresses large numbers of TGF-/3-R. The 
results from the radioreceptor assay strongly correlated with the results from the 
soft agar assay, and confirms the presence of TGF-/3 in the T cell supernatants 
(Table II). We have also tested supernatants conditioned by several different T 
cell lines and found TGF-/3 present in them. Table II shows that the human T 
cell leukemia cell line, Jurkat, constitutively secretes a moderate amount of TGF- 
To confirm the presence of TGF-/3 mRNA in activated T lymphocytes, and to 
examine the time course of expression of  TGF-/3 mRNA, human tonsillar T cells 
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TABLE II 
TGF-13 Production by Human T Lymphocytes 
Exp. Sample Soft agar assay Binding assay 
(pM) (pM) 
1 Unstimulated 2.3 4,9 
PHA 23 (10)* 21 (4.3) 
2 Unstimulated 1.6 0.62 
PHA 74 (46) 32 (56) 
3 Jurkat 14 26 
In the first experiment, tonsillar T cells were cultured for 4 d in serum- 
free media t a concentration f 2 x l0 s cells/ml in the presence or 
absence of PHA. In the second experiment, onsillar T cells were 
cultured in serum containing media in the presence or absence of 2 
#g/ml of PHA. After 48 h, the cells were harvested, washed three times, 
and recultured in serum-free media for 4 d. In the third experiment, 
Jurkat cells were cultured in serum-free media for 2 d at an initial 
concentration f 2 x 106 cells/ml. 
* Number in parentheses is the fold stimulation. 
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FIGURE 4. TGF-13 mRNA is rapidly induced in stimulated T cells. Northern blot of RNA 
obtained at various time intervals after stimulation with 2 #g/ml of PHA in serum-containing 
media. The time 0 point was cultured for 2 h in the absence of PHA. RNA was extracted 
from 10 8 cells for each time point. 15 #g of total cytoplasmic RNA was loaded per lane. 
were cu l tured with PHA for various periods of t ime. Tota l  RNA from each 
group of cells was isolated and analyzed using Nor thern  blots with the TGF-/5 
cDNA as a hybr id izat ion probe.  Fig. 4 shows the induct ion of  TGF-/3 mRNA in 
T cells at various times after st imulat ion. Unst imulated  T cells had low to 
undetectab le  l vels of  TGF-/5 mRNA,  while PHA-act ivated T cells expressed 
substantial  levels of  TGF-/5 mRNA.  The  message appeared rapidly after stimu- 
lation, and  thereafter  the level of  message was relatively constant.  In contrast o 
the rapid induct ion  and p lateauing of TGF-/3 mRNA,  the rate of  secretion of 
TGF-/3 into cu l ture supernatants  gradual ly increased ur ing  the culture and did 
not reach maximal  evels unti l  72 -96  h after st imulat ion (Fig. 5). 
Human T cells can be subdiv ided into two major  subsets on the basis of the 
expression of e i ther the T4  or the T8  surface marker.  We examined whether  
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FIGURE 5. Kinetic of TGF-13 production by activated T lymphocytes. Tonsillar T lympho- 
cytes were activated with PHA (2 #g/ml) in the presence of serum. 24 h before termination 
of the culture, the cells were harvested, washed extensively, then recultured in serum-free 
media. At the end of the culture period, the supernatants were assayed for TGF-13 activity 
using the soft agar assay. For the 0-24 h points, the cells were cultured for 2 h in the presence 
of serum, washed, and recultured in serum-free media in the presence or absence of PHA for 
24 h. The unstimulated culture contained 4 pg/ml of TGF-/5. (0), TGF-/3 secreted in the 
previous 24 h (left y axis); (0), calculated accumulation of TGF-13 to that time point (right y 
axis). 
FIGURE 6. TGF-/3 mRNA is present in both T4 and T8 lymphocytes. Peripheral blood T 
lymphocytes were separated into a T4 and T8 population using an affinity rosetting technique. 
Each fraction was >90% pure, as judged by immunofluorescence. The T4 and T8 populations 
(5.0 x 107 cells for each fraction) were stimulated with 2 #g/ml of PHA in serum containing 
media for 24 h, and after extraction of the RNA from each fraction, they were analyzed for 
the presence of TGF-/3 mRNA. 
T4 or T8 lymphocytes preferentially expressed TGF-t3 message. T cells were 
separated into T4 and T8 fractions using immune rosetting, and each fraction 
was stimulated with PHA for 24 h. Total RNA from each fraction was purified, 
and a Northern blot was performed (Fig. 6). Although both the T4 and T8 
subsets were induced to express TGF-/3 mRNA, the T4 subset expressed a 
slightly greater amount. Thus, both activated T4 and T8 cells contain mRNA 
for TGF-/3, and significant quantities of TGF-/3 are secreted by activated T cells. 
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Discussion 
This report examines the effect of TGF-/3 on human T cell proliferation and 
proposes that TGF-/3 production by T lymphocytes may be important in lympho- 
cyte immunoregulation a d T cell interactions with other cell types. We showed 
that T lymphocytes have receptors for TGF-~, which are upregulated after T 
cell activation, that the addition of exogenous TGF-/3 impaires IL-2-dependent 
T cell proliferation, and that it inhibits IL-2-induced upregulation of the IL-2-R 
and the transferrin receptor. Additionally, we confirmed the presence of TGF- 
13 mRNA in activated T cells, and determined the kinetics of TGF-~ mRNA 
induction after T cell activation. Finally, we have shown that TGF-/~ biologic 
activity is present in culture supernatants conditioned by human T cells, and that 
PHA activation results in a 10-46-fold increase in TGF-/3 production. 
We think it is unlikely that the TGF-/~ detected in the conditioned supernatants 
is related to a cell type other than T cells. The experiments described here used 
T cells purified from tonsillar mononuclear cells. These preparations were <0.5% 
esterase positive. Although there is sufficient accessory cell function to induce a 
PHA response, there are numerically very few monocytes present. Thus, it is 
unlikely that PHA would stimulate the few remaining accessory cells to make 
significant levels of TGF-/3 mRNA and to secrete the quantities of TGF-/3 we 
have detected in the conditioned supernatants. Also arguing that T cells are a 
source of TGF-~ is the production of TGF-/~ by a human T cell leukemia cell 
line. 
The means by which resting T cells are activated and induced to undergo 
clonal expansion has been intensively studied. The major pathway of T cell 
activation occurs via the interaction of appropriately processed and presented 
antigen with the T cell receptor (25-27). This interaction results in the expression 
of IL-2-R, and the synthesis and secretion of IL-2 (28, 29). Once a critical 
number of high-affinity IL-2-R on the T cell membrane have bound ligand, 
DNA synthesis and cell division occurs. Additionally, the interaction of IL-2 with 
its receptor isa positive feedback signal for the cell to further increase its number 
of IL-2-R (20, 21, 30). Whether predominantly low-affinity IL-2-R or both high- 
and low-affinity IL-2-R are increased by this interaction iscontroversial (30, 31). 
Once T cell mitosis occurs, T cells continue to express IL-2-R and to proliferate 
in response to IL-2. However, even in the presence of exogenous IL-2, the T 
cell proliferation gradually decreases. Accompanying this decrease in prolifera- 
tion is a decrease in IL-2-R expression (32). In this pathway of T cell activation 
~nd proliferation, the major regulatory signals are antigen in conjunction with 
Ia, IL-2, and IL-2-R expression. The observations reported here suggest hat 
TGF-/3 may also be an important physiologic regulator of T cell growth. 
The evidence supporting a role for TGF-/3 in the regulation of T cell growth 
includes the demonstration that the addition of exogenous TGF-13 to cultures 
inhibits IL-2-dependent T cell proliferation and blocks IL-2-induced IL-2-R 
upregulation, that receptor levels for TGF-/3 are dependent upon the state of 
cellular activation, that T cells upon activation produce mRNA for TGF-13, and 
that TGF-/3 is secreted by PHA-activated T cells in concentrations in the range 
of those capable of inhibiting T cell proliferation. 
The early synthesis of TGF-/3 mRNA at a time when the cells are being induced 
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to proliferate appears to be contradictory to this hypothesis that TGF-13 is a 
growth inhibitor. However, despite the early appearance of TGF-13 mRNA, 
significant quantities of the processed TGF-/3 protein were not secreted until 2- 
4 d later in culture. Thus, a prolonged interval sufficient for the gradual 
accumulation of TGF-/3 may be required to trigger an inhibitory signal. Further- 
more, the inhibitory effect of exogenous TGF-/3 on IL-2-dependent T cell 
proliferation can be partially overcome by the addition of a higher concentration 
of IL-2. This suggests that the balance between IL-2 and TGF-I3 may be 
important in regulating T cell proliferation. 
It has been shown (33) that TGF-13 can be secreted by certain cells in a 
biologically inert form that is unmasked by acid treatment of the culture media. 
The platelet-derived TGF-/3 used in the functional studies described here has 
been acid treated ui-ing the purification process. This leaves open the possibility 
that lymphocyte-derived TGF-/3 does not impart an inhibitory signal unless it is 
activated in some manner. Experiments are in progress to examine this possibility. 
There is a precedent for TGF-/3 being an autocrine growth inhibitor. In this 
regard, TGF-I3 and a growth inhibitor from green monkey kidney cells (BSC-1) 
have been shown to have nearly identical biologic activity, and to compete for 
binding to the same membrane receptor (13, 34). The BSC-1 cells produce the 
inhibitor when arrested at saturation density. The growth inhibitor has been 
purified from media conditioned by density-arrested cells, and has been shown 
to inhibit the proliferation of the same cells at a low cell density (34). 
The production of TGF-13 by T lymphocytes may not only be important in the 
regulation of lymphocyte function, but also may be important in the interaction 
of T cells with other cell types. For example, TGF-13 has been shown to accelerate 
wound healing (35). Collagen deposition in a healing wound generally begins 5- 
7 d after the injury (36). This is preceded by an influx of mononuclear cells. 
Although the macrophage is the predominant cell type in this cellular infiltrate, 
lymphoid cells are also present (36). T cell production of lymphokines such as 
TGF-B during this early phase of wound healing may be an important signal for 
fibroblasts to synthesize collagen (37, 38). Whether macrophages also produce 
TGF-13 is currently being investigated. 
While a resolving acute inflammatory esponse such as a healing wound results 
in minimal fibrosis, chronic inflammation can cause considerable scarring with 
subsequent tissue deformation. Areas of chronic inflammations are characterized 
by a mononuclear cell infiltrate, fibroblast proliferation, and fibroblast collagen 
production. The continued production of TGF-/3 by activated T cells in these 
inflammatory sites may be important in maintaining fibroblast collagen synthesis. 
Furthermore, aberrant TGF-/3 production by T iymphocytes may be important 
in certain diseases that are characterized byexcessive collagen production. 
Conversely, TGF-13 production by other cells may influence immune function. 
The exposure of T cells to large amounts of TGF-/3 would, very likely, severely 
limit normal T cell function. Certain tumor and virally transformed cell lines 
have been shown (2) to produce large amounts of TGF-13. The production of 
TGF-13 by tumors in vivo could enhance a tumor's ability to escape immune- 
mediated estruction. In addition to the effects of TGF-13 on T cell function, we 
have also shown that TGF-/3 inhibits NK activity (39) and B cell function (Kehrl, 
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cytes, manuscript in preparation). 
Thus, TGF-3 production by T lymphocytes may have two roles in inflamma- 
tory foci: the first to limit T and B cell clonal expression and subsequent effector 
function by a feedback mechanism, and second, to stimulate fibroblast prolifer- 
ation and collagen production. By limiting T cell clonal expansion and presum- 
ably further T cell TGF-3 secretion, the production of TGF-3 by T lymphocytes 
may be an important signal in the regulation of inflammation. 
Summary 
This study examines the potential role of transforming rowth factor 3 (TGF- 
3) in the regulation of human T lymphocyte proliferation, and proposes that 
TGF-3 is an important autoregulatory l mphokine that limits T lymphocyte 
clonal expansion, and that TGF-3 production by T lymphocytes i  important in 
T cell interactions with other cell types. TGF-3 was shown to inhibit IL-2- 
dependent T cell proliferation. The addition of picograms amounts of TGF-3 to 
cultures of IL-2-stimulated human T lymphocytes suppressed DNA synthesis by 
60-80%. A potential mechanism of this inhibition was found. TGF-3 inhibited 
IL-2-induced upregulation of the IL-2 and transferrin receptors. Specific high- 
affinity receptors for TGF-3 were found both on resting and activated T cells. 
Cellular activation was shown to result in a five- to sixfold increase in the number 
of TGF-3 receptors on a per cell basis, without a change in the affinity of the 
receptor. Finally, the observations that activated T cells produce TGF-3 mRNA 
and that TGF-3 biologic activity is present in supernatants conditioned by 
activated T cells is strong evidence that T cells themselves are a source of TGF- 
3. Resting T cells were found to have low to undetectable l vels of TGF-3 
mRNA, while PHA activation resulted in a rapid increase in TGF-3 mRNA 
levels (within 2 h). Both T4 and T8 lympocytes were found to make mRNA for 
TGF-3 upon activation. Using both a soft agar assay and a competitive binding 
assay, TGF-3 biologic activity was found in supernatants conditioned by T cells; 
T cell activation resulted in a 10-50-fold increase in TGF-3 production. Thus, 
TGF-3 may be an important antigen-nonspecific regulator of human T cell 
proliferation, and important in T cell interaction with other cell types whose 
cellular functions are modulated by TGF-3. 
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